News|Articles|November 18, 2026

Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLC

Author(s)OncLive Staff
Fact checked by: Caroline Seymour
Listen
0:00 / 0:00

Key Takeaways

  • First-line calderasib/pembrolizumab achieved ORR 71%, DCR 93%, median DOR 33.0 months, and median PFS 28.8 months in PD-L1 TPS ≥1% KRAS G12C metastatic NSCLC.
  • PD-L1 enrichment was evident, with TPS ≥50% yielding ORR 84% and median PFS 34.4 months versus ORR 55% and median PFS 25.1 months for TPS 1%–49%.
SHOW MORE

First-line calderasib plus pembrolizumab (Keytruda) produced durable responses and prolonged progression-free survival (PFS) in patients with KRAS G12C–mutated metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 1% or higher, according to updated results from the phase 1 KANDLELIT-001 trial (NCT05067283) presented at the 2026 ESMO Congress.1

At a July 22, 2026, data cutoff, the objective response rate (ORR) with calderasib plus pembrolizumab was 71% (95% CI, 62%-78%) among efficacy-evaluable patients with a TPS of 1% or higher (n = 122), with a median duration of response (DOR) of 33.0 months (range, 1.2+ to 45.3+) and a median PFS of 28.8 months (95% CI, 20.6-not reached [NR]). Among patients with a TPS of 50% or higher (n = 64), the ORR was 84% (95% CI, 73%-92%), the median DOR was NR (range, 1.2+ to 36.2+), and the median PFS was 34.4 months (95% CI, 21.8-NR). Among those with a TPS of 1% to 49% (n = 58), the ORR was 55% (95% CI, 42%-68%), the median DOR was 26.2 months (range, 1.4+ to 45.3+), and the median PFS was 25.1 months (95% CI, 10.5-NR).

The disease control rate (DCR) was 93% (95% CI, 87%-97%) in the overall population with a TPS of 1% or higher. The 6- and 12-month PFS rates were 86% and 71%, respectively, in the overall population; 90% and 76% in patients with a TPS of 50% or higher; and 80% and 65% in those with a TPS of 1% to 49%.

Key Takeaways From the Updated KANDLELIT-001 NSCLC Analysis

  • First-line calderasib plus pembrolizumab yielded an ORR of 71% and a median PFS of 28.8 months in patients with KRAS G12C–mutated NSCLC and a TPS of 1% or higher.
  • In patients with a TPS of 50% or higher, the ORR was 84% and the median PFS was 34.4 months.
  • Calderasib monotherapy produced an ORR of 35% in previously treated KRAS G12C–mutated NSCLC.
  • The doublet is being evaluated in 2 ongoing phase 3 first-line trials.

“Our findings support enrollment in the phase 3 KANDLELIT-004 (NCT06345729) and KANDLELIT-007 (NCT07190248) studies of calderasib plus pembrolizumab as first-line therapy in KRAS G12C–mutated metastatic NSCLC,” said Mehmet Ali Nahit Şendur, MD, of Ankara Yıldırım Beyazıt University and Ankara Bilkent City Hospital in Türkiye, who presented the data.

How was the phase 1 KANDLELIT-001 trial of calderasib in KRAS G12C–mutated NSCLC designed?

KANDLELIT-001 is an ongoing, open-label, phase 1 study of calderasib, an oral KRAS G12C inhibitor, given alone or in combination. Arms 1 and 3 enrolled patients with previously treated, locally advanced unresectable or metastatic solid tumors (n = 271), including patients with NSCLC (n = 144), who received calderasib at 25 to 800 mg/day orally. In arm 2, patients with previously untreated metastatic NSCLC and a TPS of 1% or higher (n = 136) received calderasib at 25 to 400 mg/day plus pembrolizumab at 200 mg intravenously every 3 weeks for up to 35 cycles. In arm 4, patients with previously untreated metastatic NSCLC and any TPS (n = 46) received the same doublet plus carboplatin (area under the concentration–time curve 5 mg/mL/min) intravenously every 3 weeks for 4 cycles and pemetrexed at 500 mg/m² intravenously every 3 weeks.

Eligible patients had KRAS G12C mutations confirmed by histologic or blood-based testing, an ECOG performance status of 0 or 1, and measurable disease per RECIST v1.1. The primary end points were the incidence of dose-limiting toxicities (DLTs), adverse effects (AEs), and AEs leading to discontinuation. Secondary end points included ORR and DOR per RECIST v1.1 by investigator assessment and pharmacokinetics; PFS was an exploratory end point.

What did earlier KANDLELIT-001 results show for calderasib plus pembrolizumab in NSCLC?

Results from KANDLELIT-001 were previously presented at the 2026 European Lung Cancer Congress.2,3 In that analysis, calderasib plus pembrolizumab elicited an ORR of 72% (95% CI, 63%-81%) and a median PFS of 28.9 months (95% CI, 20.6-NR) among patients with a TPS of 1% or higher (n = 98). Among patients with a TPS of 50% or higher (n = 54), the ORR was 87% (95% CI, 75%-95%) and the median PFS was NR. Calderasib monotherapy produced an ORR of 27% (95% CI, 16%-40%) among patients with NSCLC (n = 59), and in the triplet arm (n = 46), the median PFS was 15.1 months (95% CI, 10.5-NR).

How did calderasib monotherapy and the triplet regimen perform in KRAS G12C–mutated NSCLC?

Among efficacy-evaluable patients with previously treated NSCLC who received calderasib monotherapy (n = 103) in the updated analysis, the ORR was 35% (95% CI, 26%-45%) and the DCR was 78% (95% CI, 68%-85%).1 The median DOR was 16.8 months (range, 1.2+ to 36.1+), and the median PFS was 8.3 months (95% CI, 6.0-16.4), with 6- and 12-month PFS rates of 62% and 40%, respectively.

In the triplet arm (n = 46), calderasib plus pembrolizumab and chemotherapy produced an ORR of 65% (95% CI, 50%-79%) and a DCR of 89% (95% CI, 76%-96%). The median DOR was 19.4 months (range, 1.9+ to 27.4+), and the median PFS was 17.6 months (95% CI, 10.5-26.3); the 6- and 12-month PFS rates were 82% and 66%, respectively.

What was the safety profile of calderasib-based regimens in KANDLELIT-001?

Any-grade treatment-related adverse effects (TRAEs) occurred in 61% of patients in the monotherapy arms, which included all solid tumors (n = 271); 89% of patients in arm 2 (n = 136); and 98% of patients in arm 4 (n = 46). Grade 3 TRAEs occurred in 7%, 25%, and 59% of patients, respectively, and grade 4 TRAEs occurred in less than 1%, 4%, and 11%. One patient in arm 2 had grade 5 treatment-related myelosuppression and decreased platelet count, and 1 patient in arm 4 had grade 5 treatment-related immune-mediated myositis; no treatment-related deaths occurred with monotherapy.

TRAEs led to calderasib discontinuation in 1%, 4%, and 7% of patients in the monotherapy, doublet, and triplet arms, respectively, and to pembrolizumab discontinuation in 24% of patients in arm 2 and 30% of those in arm 4. The most common TRAEs with calderasib plus pembrolizumab were increased aspartate aminotransferase levels (AST; 35%), increased alanine transaminase levels (ALT; 32%), and pruritus (27%); with the triplet, they were anemia (48%), increased ALT (43%), and increased AST (43%). DLTs occurred in 1% of evaluable patients in the monotherapy arms (n = 107), 6% in arm 2 (n = 34), and 11% in arm 4 (n = 46).

What are the next steps for calderasib plus pembrolizumab in first-line KRAS G12C–mutated NSCLC?

The investigators concluded that the findings support enrollment in 2 ongoing phase 3 trials of calderasib plus pembrolizumab as first-line therapy for KRAS G12C–mutated metastatic NSCLC. The randomized, double-blind, phase 3 KANDLELIT-004 trial (NCT06345729) is comparing calderasib plus pembrolizumab vs placebo plus pembrolizumab in patients with a TPS of 50% or higher. The randomized, open-label, phase 3 KANDLELIT-007 trial (NCT07190248) is comparing calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) vs subcutaneous pembrolizumab plus chemotherapy in patients with nonsquamous disease.

Disclosures: Şendur reported receiving payment or honoraria for lectures, presentations, or speakers bureaus from Roche, AstraZeneca, Pfizer, Novartis, Astellas, BMS, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD), Eli Lilly, Gilead, Takeda, Centurion, and Menarini Stemline; receiving support for meeting attendance and/or travel from Roche, Centurion, and Menarini; and participating on a data safety monitoring board or advisory board for Roche, AstraZeneca, Pfizer, Novartis, Astellas, BMS, MSD, Eli Lilly, Gilead, Takeda, Centurion, and Menarini Stemline.

References

  1. Gray JE, Peled N, Liu L, et al. Calderasib (MK-1084), alone or in combination, for KRAS G12C-mutant metastatic non-small cell lung cancer. Presented at: 2026 ESMO Congress; October 23-27, 2026; Madrid, Spain. Abstract 2680RO.
  2. Sacher A, Rottenberg Y, Kwiatkowski M, et al. Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated metastatic non–small-cell lung cancer enrolled in KANDLELIT-001. Presented at: 2026 European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark. Abstract 4MO.
  3. Seymour C. Calderasib-based therapy drives high responses in KRAS G12C–mutant metastatic NSCLC. OncLive. Published March 26, 2026. Accessed November 16, 2026. https://www.onclive.com/view/calderasib-based-therapy-drives-high-responses-in-kras-g12c-mutant-metastatic-nsclc

Related to this article